SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Pioneering CAR T-Cell Therapy for Advanced Gastric Cancer
CAR T-Cell Therapy has reached a historic milestone with the approval of satri-cel, the world’s first authorized CAR T treatment for any solid tumor. The therapy targets Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after at l...
Pharmaceutical Innovation Benefits Driving Socioeconomic Returns in Europe
Pharmaceutical innovation benefits extend well beyond clinical gains, delivering €5.67 in socioeconomic value for every additional euro spent on newer therapies across 29 European countries from 2014 to 2024. By reducing premature mortality, cutting hospital stays, and increasing workforce partic...
Breakthrough Results with Tulisokibart in Ulcerative Colitis Phase 3 Trial
Tulisokibart ulcerative colitis therapy has achieved a critical milestone, becoming the first anti-TL1A monoclonal antibody to demonstrate clinical remission at week 12 in a Phase 3 trial of patients with moderately to severely active disease. Developed to interrupt immuno-fibrosis — the linked p...